These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8845569)

  • 61. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage.
    Mozaffari F; Hansson L; Kiaii S; Ju X; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
    Br J Haematol; 2004 Feb; 124(3):315-24. PubMed ID: 14717778
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
    Jourdan M; De Vos J; Mechti N; Klein B
    Cell Death Differ; 2000 Dec; 7(12):1244-52. PubMed ID: 11175262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
    Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
    Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The retinoblastoma susceptibility gene RB-1 in multiple myeloma.
    Juge-Morineau N; Harousseau JL; Amiot M; Bataille R
    Leuk Lymphoma; 1997 Jan; 24(3-4):229-37. PubMed ID: 9156653
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
    Tamura H; Ishibashi M; Yamashita T; Tanosaki S; Okuyama N; Kondo A; Hyodo H; Shinya E; Takahashi H; Dong H; Tamada K; Chen L; Dan K; Ogata K
    Leukemia; 2013 Feb; 27(2):464-72. PubMed ID: 22828443
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
    Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
    Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.
    Belani R; Weiner GJ
    Immunology; 1996 Feb; 87(2):271-4. PubMed ID: 8698390
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
    Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
    Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
    Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
    Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.
    Billadeau D; Ahmann G; Greipp P; Van Ness B
    J Exp Med; 1993 Sep; 178(3):1023-31. PubMed ID: 8350044
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Growth control mechanisms in multiple myeloma.
    Hawley RG; Berger LC
    Leuk Lymphoma; 1998 May; 29(5-6):465-75. PubMed ID: 9643560
    [TBL] [Abstract][Full Text] [Related]  

  • 72. How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2?
    Kovacs E
    Biomed Pharmacother; 2003 Dec; 57(10):489-94. PubMed ID: 14637393
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells.
    Kubin M; Kamoun M; Trinchieri G
    J Exp Med; 1994 Jul; 180(1):211-22. PubMed ID: 7516408
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation.
    Skapenko A; Lipsky PE; Kraetsch HG; Kalden JR; Schulze-Koops H
    J Immunol; 2001 Apr; 166(7):4283-92. PubMed ID: 11254680
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multiple myeloma: new aspects of biology and treatment.
    Ozaki S; Kosaka M
    J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
    [TBL] [Abstract][Full Text] [Related]  

  • 76. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
    Fallarino F; Fields PE; Gajewski TF
    J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Function of B7/CD28 in anti-myeloma immunoreaction through activating T cells].
    Guo L; Zhang X; Qiu Y
    Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):235-8. PubMed ID: 11601210
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of interleukin 6 in the growth of myeloma-derived cell lines.
    Barut BA; Zon LI; Cochran MK; Paul SR; Chauhan D; Mohrbacher A; Fingeroth J; Anderson KC
    Leuk Res; 1992 Oct; 16(10):951-9. PubMed ID: 1405708
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells.
    Smith MR; Xie T; Joshi I; Schilder RJ
    Br J Haematol; 1998 Sep; 102(4):1090-7. PubMed ID: 9734662
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.